Volume 29, Issue 159, May 2025

Pharmacotherapy of obesity - Amylin Analogs and Dual Amylin-Calcitonin Receptor Agonists. A literature review

Karolina Woźniak^1♦, Michał Stasiak², Adam Woźniak¹, Franciszek Glapiński², Wiktor Żyro¹, Katarzyna Żyro³

¹St. Anne's Trauma Surgery Hospital, Barska Str. 16/20, 02-315 Warsaw, Poland
² Central Clinical Hospital, 1a Banacha Str. 02-097 Warsaw, Poland
³Independent Public Health Care Facilities in Pruszków, al. Armii Krajowej 2/4, 05-800 Pruszków, Poland

^♦Corresponding author
St. Anne's Trauma Surgery Hospital, Barska Str. 16/20, 02-315 Warsaw, Poland

ABSTRACT

Obesity has become one of the biggest challenges in medicine. Hundreds of millions of people struggle with this disease. It has a significant impact on mortality rates. Therefore, the search for new therapies is essential. This review aims to analyze Amylin Analogs and Dual Amylin-Calcitonin Receptor Agonists (DACRAs). These are new drugs tested for the treatment of diabetes and excess body weight. We will focus on their use in the treatment of obesity. Recent advances in gut hormone-modulating medications have implicated a possible mechanism by which the amylin-calcitonin pathway may help control body weight. Amylin Analogs, pramlintide, and cagrilintide exhibit encouraging efficacy in clinical studies. In preclinical studies, DACRAs KBP-066, KBP-088, and KBP-089 caused significant weight loss and metabolic effects. Mechanistic accounts reveal the complex neural networks and receptor dynamics that the therapies utilize. Amylin Analogs and DACRAs represent a novel platform for obesity treatment, but we need to translate preclinical evidence into everyday practice with patients. Conducting further studies to establish the dosage and possibly reduce side effects is essential.

Keywords: Obesity, Amylin, Calcitonin, Weight Management, Gastrointestinal Hormones

Medical Science, 2025, 29, e62ms3558

PDF

DOI: https://doi.org/10.54905/disssi.v29i158.e62ms3558

Published: 03 May 2025